Mubritinib

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Mubritinib
Mubritinib structure.png
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C25H23F3N4O2
Molar mass 468.47 g/mol
3D model (JSmol)

Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.[1][2][3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.[4]

Synthesis[edit]

Mubritinib.png

See also[edit]

References[edit]